A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients

Clinical Infectious Diseases

Volumn 47, Issue 7, 2008, Pages 885-892

  Kumar, Deepali ^a   Chen, Maggie Hong ^b   Wong, Gary ^c   Cobos, Isabel ^a   Welsh, Brenda ^b   Siegal, Deborah ^d   Humar, Atul ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; INTERFERON; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PNEUMOCOCCUS VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEVER; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SINGLE DRUG DOSE; VACCINATION;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 52449104895     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/591537     Document Type: Article

References (25)

1. Kumar D, Humar A, Plevneshi A, et al. Invasive pneumococcal disease in solid organ transplant recipients - 10-year prospective population surveillance. Am J Transplant 2007; 7:1209-14.
2. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004; 4(Suppl 10):160-3.
3. Centers for Disease Control and Prevention. Recommended adult immunization schedule - United States, October 2006-September 2007. MMWR Morb Mortal Wkly Rep 2006; 55:1-4.
4. Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients - three year follow-up of a randomized trial. Am J Transplant 2007; 7:633-8.
5. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187:1639-45.
6. McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 2000; 181:757-60.
7. Blumberg EA, Brozena SC, Stutman P, Wood D, Phan HM, Musher DM. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis 2001; 32:307-10.
8. Eskola J. Immunogenicity of pneumococcal conjugate vaccines. Pediatr Infect Dis J 2000; 19:388-93.
9. Powers DC, Anderson EL, Lottenbach K, Mink CM. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996; 173:1014-8.
10. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001; 20:545-53.
11. Vernacchio L, Romero-Steiner S, Martinez JE, et al. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease. J Infect Dis 2000; 181:1162-6.
12. Chan CY, Molrine DC, George S, et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996; 173:256-8.
13. Lesprit P, Pedrono G, Molina J, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21:2425-34.
14. Edwards KM, Griffin MR. Great expectations for a new vaccine. N Engl J Med 2003; 349:1312-4.
15. Molrine DC, Hibberd PL. Vaccines for transplant recipients. Infect Dis Clin North Am 2001; 15:273-305, xii.
16. Pneumococcal vaccine. Canada immunization guide. 7th ed. Ottawa: Public Health Agency of Canada, 2006.
17. Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immuno-sorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003; 10:514-9.
18. Romero-Steiner S, Libutti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997; 4:415-22.
19. Martinez JE, Romero-Steiner S, Pilishvili T, et al. A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine. Clin Diagn Lab Immunol 1999; 6:581-6.
20. World Health Organization. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series No. 927. Geneva: World Health Organization, 2005.
21. Lin PL, Michaels MG, Green M, et al. Safety and immunogenicity of the American Academy of Pediatrics - recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics 2005; 116:160-7.
22. MacLennan J, Obara S, Deeks J, et al. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 2001; 183:97-104.
23. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7:597-606.
24. Smith KG, Isbel NM, Catton MG, Leydon JA, Becker GJ, Walker RG. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998; 13:160-4.
25. Scharpé J, Evenepoel P, Maes B, et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 2008; 8:332-7.